Mercia Asset Management PLC is pleased to announce its participation in significant funding rounds for two of its direct investment portfolio companies, Warwick Acoustics Limited and Axis Spine Technologies Limited. These investments reflect the continued commercial progress of both companies and the potential for their respective technologies. The funding rounds also underscore their ability to
Mercia Asset Management PLC is pleased to provide a trading summary for the financial year ended 31 March 2025 (“FY25”). The benefits of Mercia’s increasing scale are now beginning to feed their way into the Group’s overall financial performance. Together with a continuing focus on efficiency, Mercia now expects its EBITDA for FY25 to be
Mercia Asset Management PLC is pleased to announce the appointment of Dean Heaney as Head of Institutional Distribution. Dean will lead Mercia’s distribution strategy across its venture, debt, private equity and real assets strategies. Dean most recently led the UK institutional business at Franklin Templeton, a $1.5trillion asset manager, with expertise across both public and
CEO Dr Mark Payton joined Proactive’s Stephen Gunnion to talk through Mercia’s FY25 Interim Results which showcased strong growth and operational milestones. Dr Payton reflected on a decade of accomplishments since Mercia’s listing, highlighting £1.6 billion in third-party funds under management and investments of over £1 billion across the UK, predominantly outside London. .
Mercia’s FY25 Interim Results presentation, presented by Dr Mark Payton, Chief Executive Officer and Martin Glanfield, Chief Financial Officer. Visit Mercia’s Interim Results area
Mercia Asset Management PLC is pleased to announce its interim results for the six months ended 30 September 2024. Mark Payton, Chief Executive Officer of Mercia, commented: “Mercia has delivered another strong first half performance with our higher funds under management driving revenue and EBITDA growth. I am pleased to say that none of the
Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has entered into a strategic co-marketing agreement with Agilent Technologies, a leading tools provider in the genomics sector. The agreement offers select customers the opportunity to access Tagomics’ and Agilent Technologies’ combined innovative offerings through an exclusive technology access program hosted out of
Scalpel AI, a London-based medtech start-up transforming the management of surgical tools and implants using computer vision, has raised £3.8m ($4.8m) in a funding round led by Mercia Ventures, with participation from Tensor Ventures and private investors. The investment will enable Scalpel AI to scale its global operations and roll out its technology with major
Semble, an integrated clinical system and leading innovator in healthtech, has raised $15m (£11.5m) in a Series B funding round led by Mercia Ventures, with participation from Octopus Ventures, Smedvig Ventures and Triple Point. The investment will enable the London-based company to consolidate its position in the UK market and expand its presence in France,
Mercia Ventures-backed Wobble Genomics, a healthcare and biotechnology company at the forefront of long-read RNA sequencing, will present data today demonstrating that its technology can detect rare full-length RNA transcript variants not picked up by other methods. 1 Wobble’s technology utilised full-length RNA transcripts as biomarkers to achieve early-stage breast cancer detection with 80% sensitivity